These findings, published in JAMA, support the use of perioperative dapagliflozin as a preventive strategy to lower the risk of postoperative AKI in patients undergoing elective cardiac surgery. Acute kidney injury is a frequent complication after cardiac surgery, affecting an estimated 2% to 50% of patients and increasing the risk of prolonged hospitalization, kidney failure, and death. Although several preventive approaches have been explored, no medication has been established as a standard strategy to reduce postoperative AKI. The multicenter, double-blind, placebo-controlled randomized clinical trial enrolled 784 adults undergoing elective cardiac surgery at seven hospitals in the Netherlands between June 2023 and January 2025. Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.